Catalent (CTLT) Osake Kurssi
Catalent Kurssi
Viimeisten 15 vuoden aikana Catalentn liikevaihto kasvoi 7,9 % vuodessa ja ylsi 4,38 Mrd. USD:een. Osakekohtainen tulos on kasvanut 46,7 % vuodessa viimeisten 8 vuoden aikana. Catalentn nettomarginaali −23,8 % on laskenut verrattuna 5,6 %:iin muutama vuosi sitten. Catalentn 12 kuukauden konsensustavoitehinta on 64,77 USD, noin yli kurssia 2,0 %. 14 analyytikosta 0 suosittaa ostoa — kokonaiskonsensus on Pidä.
Catalent osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Catalent liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Catalent -osakkeesta
Catalent Inc is a leading provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With its strategic approach, Catalent offers a broad range of integrated services to ensure efficient drug development and delivery. The company's business model focuses on collaborating with pharmaceutical and biotechnology companies to accelerate their product development process and bring innovative therapies to market. By leveraging its expertise in formulation and development, advanced delivery systems, and manufacturing solutions, Catalent helps its clients optimize their chances of success while delivering high-quality products to patients worldwide.
Catalent Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Catalent Inc in the market include Thermo Fisher Scientific Inc, Lonza Group Ltd, and Patheon N.V.
Catalent Inc is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With a rich history spanning over 80 years, Catalent has established itself as a trusted partner to pharmaceutical and biotech companies worldwide. The company was founded in 2007 through the merger of RP Scherer Corporation and Cardinal Health's pharmaceutical technologies and services segment. Catalent Inc has continuously evolved and expanded its capabilities, offering a wide range of solutions including drug development, manufacturing, packaging, and supply chain services. Today, Catalent Inc is recognized for its innovative approach, cutting-edge technologies, and commitment to delivering exceptional customer value in the healthcare industry.
Catalent Inc, a leading global provider of advanced delivery technologies and development solutions, has achieved numerous significant milestones over the years. One notable achievement is its successful acquisition of Cook Pharmica LLC, which expanded its biologics development and manufacturing capabilities. Additionally, the company has strengthened its global presence by opening new facilities in strategic locations, such as a state-of-the-art biomanufacturing facility in Bloomington, Indiana. Catalent Inc has also received various awards and recognition for its innovation, including being named the Contract Development and Manufacturing Organization of the Year by Pharma Integrates. These milestones highlight Catalent Inc's commitment to growth, innovation, and delivering advanced solutions to its customers.
Catalent Inc is primarily present in multiple countries and regions. With a global presence, this innovative company operates in North America, Europe, Asia Pacific, and Latin America. Catalent Inc has established manufacturing, development, and distribution facilities in various locations across the United States, including New Jersey, Indiana, and Maryland. In Europe, the company operates in multiple countries, including the United Kingdom, Germany, and Italy. In the Asia Pacific region, Catalent Inc has a strong presence in China, Singapore, and Japan. Additionally, the company has operations in Brazil, Argentina, and Mexico, among other countries in Latin America.
Catalent Inc represents key values of innovation, collaboration, and customer focus. With a corporate philosophy centered on driving exceptional experiences and outcomes for patients and customers, Catalent is committed to delivering advanced solutions for the development and manufacturing of pharmaceutical products. The company's dedication to scientific excellence and quality ensures the precise delivery and reliable supply of medicines to improve health globally. Catalent's strong expertise in drug delivery technologies, development solutions, and manufacturing capabilities positions them as a trusted partner in the pharmaceutical industry. Emphasizing continuous improvement and sustainable practices, Catalent Inc remains dedicated to making a meaningful impact in healthcare.
Analyytikot asettavat tällä hetkellä Catalent-osakkeelle keskimääräisen tavoitehinnan 64,77 USD (mediaani: 64,77 USD), mikä merkitsee +2,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 14 analyytikkoarvioon.
14 analyytikkoa arvioi tällä hetkellä Catalent-osaketta: 0 suosittaa ostoa, 11 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Catalent-yhtiöltä 5,00 Mrd. USD liikevaihtoa ja 1,75 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Catalent-osake noteerataan hintaan 56,54 EUR (63,48 USD).
Catalent-osake (CTLT) on listattuna 4 pörssissä, muun muassa: NYSE (CTLT), SIX (Zürich) (0C8.SW), Frankfurt (0C8.F), München (0C8.MU).
Catalent Inc. is a globally operating company that focuses on the development and manufacturing of pharmaceuticals, as well as supporting biotech and pharmaceutical companies. It operates in three business segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. These segments offer a variety of products and services tailored to the different needs of biotech and pharmaceutical companies. Catalent Inc. earns revenue through the sale of its products and services, as well as partnerships and collaborations with other companies. It works closely with its customers to develop customized solutions and achieve a high level of customer satisfaction.
odotettu liikevaihto Catalent on 5,00 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Catalent on 318,65 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Catalent:n hinta-voitto-suhde (P/E) on tällä hetkellä 36,26. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Catalent-osakkeen arvostusta.
Catalent:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,31. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Catalent-osakkeen arvostuskennuslukuna.
Catalent:n Eulpool-laatuscore on 2/10.
Catalent:n ISIN on US1488061029. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Catalent:n WKN on A112H2. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Catalent:n ticker on CTLT. Tämä pörssinoteeraus käytetään Catalent-osakkeiden kauppaan pörssissä.
Catalent osake
Catalent vertaisryhmä
Catalent Ticker
Catalent FIGI
Kaikki tunnusluvut ja syvällinen analyysi Catalent:sta
Meidän osakeanalyysimme Catalent-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Catalent:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: